Safety and tolerability profile of linezolid containing regimens in multidrug-resistant tuberculosis adults: the current scientific evidence
| First author [ref.] | Adverse events | Discontinuation rate | Anaemia | Neuropathy | GI events | Duration of exposure days |
| Observational studies | ||||||
| Sotgiu [31] | 63/107 (58.9) | 54/79 (68.4) | 32/84 (38.1) | 40/85 (47.1) | 14/84 (16.7) | 300# |
| Zhang [35] | 6/15 (40.0) | 4/15 (26.6) | 1/15 (6.7) | 3/15 (20.0) | 60# | |
| Xu [36] | 17/18 (94.4) | 12/18 (66.7) | 11/18 (61.1) | 15/18 (83.3) | 180¶ | |
| Experimental studies | ||||||
| Lee [32] | 33/38 (87) | 3/38 (7.9)+ | 7/38 (18.4) | 21/38 (55.3) | At least 180 | |
| Tang [34] | 27/33 (81.8) | 2/33 (6.1)+ | 17/33 (51.5) | 8/33 (24.2) | 16/33 (48.5) | 360¶ |
Data are presented as n/N (%), unless otherwise stated. GI: gastrointestinal. #: median; ¶: mean; +: permanent.